One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial
Adrian D. Elliott, PHD, a,b Christian V. Verdicchio, PH D, a Rajiv Mahajan, MD, PH D, a,c Melissa E. Middeldorp, P HD, a,b Celine Gallagher, P HD, a,b Ricardo S. Mishima, MD, P HD, a,b Jeroen M.L. Hendriks, PHD, a,b,d Rajeev K. Pathak, MD, PHD, a,e Gijo Thomas, PH D, a Dennis H. Lau, MBBS, PH D, a,b Prashanthan Sanders, MBBS, PHD
doi : 10.1016/j.jacep.2022.12.002
Volume 9, Issue 4, April 2023, Pages 455-465
Time to Get Moving: Exercise for Atrial Fibrillation∗
Alexis L. Beatty, MD, MAS, a,b Gregory M. Marcus, MD, MAS
doi : 10.1016/j.jacep.2023.02.024
Volume 9, Issue 4, April 2023, Pages 466-467
Very High-Power Short-Duration, Temperature-Controlled Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: The Prospective Multicenter Q-FFICIENCY Trial
Jose Osorio, MD, a Ayman A. Hussein, MD,b M. Craig Delaughter, MD, PHD, c George Monir, MD,d Andrea Natale, MD,e Srinivas Dukkipati, MD, f Saumil Oza, MD,g Emile Daoud, MD,h Luigi Di Biase, MD, P HD, i Moussa Mansour, MD,j Robert Fishel, MD, k Miguel Valderrabano, MD,l Kenneth Ellenbogen, MD,m on behalf of the Q-FFICIENCY Trial Investigators
doi : 10.1016/j.jacep.2022.10.019
Volume 9, Issue 4, April 2023, Pages 468-480
QDOT MICRO (QDM) is a novel contact force–sensing catheter optimized for temperature-controlled radiofrequency (RF) ablation. The very high-power short-duration (vHPSD) algorithm modulates power, maintaining target temperature during 90 W ablations for ≤4 seconds.
Pulsed Field Ablation to Treat Atrial Fibrillation: Autonomic Nervous System Effects
Daniel R. Musikantow, MD,a Petr Neuzil, MD, PHD, b Jan Petru, MD,b Jacob S. Koruth, MD, a Stepan Kralovec, MD, b Marc A. Miller, MD,a Mortioshi Funasako, MD,b Milan Chovanec, MD,b Mohit K. Turagam, MD, a William Whang, MD,a Lucie Sediva, MD, b Srinivias R. Dukkipati, MD, a Vivek Y. Reddy, MD a,
doi : 10.1016/j.jacep.2022.10.028
Volume 9, Issue 4, April 2023, Pages 481-493
During atrial fibrillation ablations using thermal energy, the treatment effect is attributed to not just pulmonary vein isolation (PVI), but also to modulation of the autonomic nervous system by ablation of cardiac ganglionated plexi (GP).
Impact of Pulsed Field Ablation on Autonomic Nervous System: Unwinding Ariadne's Thread∗
Stefanos Zafeiropoulos, MD, MSC ,a Stavros Stavrakis, MD, PH D
doi : 10.1016/j.jacep.2022.11.024
Volume 9, Issue 4, April 2023, Pages 494-496
Safety and Efficacy of a Novel Approach to Pulmonary Vein Isolation Using Prolonged Apneic Oxygenation
James K. Gabriels, MD, a Xiaohan Ying, MD, a Subhanik Purkayastha, BS, a Eric Braunstein, MD, a Christopher F. Liu, MD, a Steven M. Markowitz, MD, a Stavros Mountantonakis, MD, b George Thomas, MD, a Bruce Goldner, MD, c Jonathan Willner, MD, d Rajat Goyal, MD, e James E. Ip, MD, a Bruce B. Lerman, MD, a Jane Carter, MD, f Nicola Bereanda, MD, g Meghann M. Fitzgerald, MD, h Diana Anca, MD, h Apoor Patel, MD, i Jim W. Cheung, MD
doi : 10.1016/j.jacep.2022.10.030
Volume 9, Issue 4, April 2023, Pages 497-507
Improved ablation catheter–tissue contact results in more effective ablation lesions. Respiratory motion causes catheter instability, which impacts durable pulmonary vein isolation (PVI).
Hold Your Breath and Fasten Your Seat Belt: Prolonged Apneic Oxygenation in Pulmonary Vein Isolation∗
Luigi Di Biase, MD, P HD, Fengwei Zou, MD
doi : 10.1016/j.jacep.2022.11.031
Volume 9, Issue 4, April 2023, Pages 508-510
Very High-Power Ablation for Contiguous Pulmonary Vein Isolation: Results From the Randomized POWER PLUS Trial
Louisa O’Neill, MD, P HD, a Milad El Haddad, PH D, a Benjamin Berte, MD, PH D, b Richard Kobza, MD,b Gabriela Hilfiker, MD, a,b Daniel Scherr, MD,c Martin Manninger, MD, PH D, c Adrianus P. Wijnmaalen, MD, PH D, d Serge A. Trines, MD, P HD, d Jean-Yves Wielandts, MD, P HD, a Kris Gillis, MD, PHD, a Michelle Lycke, PH D, a Benjamin De Becker, MD,a Rene Tavernier, MD, PHD, a Jean-Benoit Le Polain De Waroux, MD, PH D, a Sebastien Knecht, MD, PH D, a Mattias Duytschaever, MD, PH D
doi : 10.1016/j.jacep.2022.10.039
Volume 9, Issue 4, April 2023, Pages 511-522
Very high-power, short-duration (90-W/4-second) ablation for pulmonary vein isolation (PVI) may reduce procedural times. However, shorter applications with higher power may impact lesion quality.
Have We Found the Optimal Strategy for Pulmonary Vein Isolation Yet?∗
Helmut Pürerfellner, MD, Georgios Kollias, MD
doi : 10.1016/j.jacep.2022.12.026
Volume 9, Issue 4, April 2023, Pages 523-525
Electrogram Morphology Recurrence for Mapping Persistent Atrial Fibrillation: Initial vs Redo Catheter Ablation
Ghaith Zaatari, MD, a, * Raul Mitrani, MD, a, * Jorge Bohorquez, P HD, b Jason Ng, P HD, c Justin Ng, MS, d Harold Rivner, MD, a Alex Velasquez, MD, a Litsa Lambrakos, MD, a Rishi Arora, MD, d Jeffrey J. Goldberger, MD, MBA
doi : 10.1016/j.jacep.2022.11.003
Volume 9, Issue 4, April 2023, Pages 526-540
Electrogram (EGM) morphology recurrence (EMR) mapping of persistent atrial fibrillation (AF) quantifies consistency of activation and is expected to be high and rapid near AF drivers.
Mapping Persistent Atrial Fibrillation: Searching for Signal in the Noise∗
Eric Buch, MD, MS, Duc H. Do, MD, MS
doi : 10.1016/j.jacep.2022.12.004
Volume 9, Issue 4, April 2023, Pages 541-542
Marked QTc Reduction Immediately Following Direct Current Cardioversion of Atrial Fibrillation: Clinical Implications and Mechanisms
Arthur Omondi, MD, a Natee Sirinvaravong, MD,a Jenna Spears, MB BC H , BAO,a Samuel Sauerwein, MD, a Roy Taoutel, MD, a Steven Liskov, MD, a Chuanyu Gao, MD, b Tong Liu, MD, PH D, c Peter R. Kowey, MD, a,d Gan-Xin Yan, MD, PHD
doi : 10.1016/j.jacep.2022.10.031
Volume 9, Issue 4, April 2023, Pages 543-554
The QTc in sinus rhythm (SR) following direct current cardioversion (DCCV) of atrial fibrillation (AF) is commonly used as a baseline QTc for patients who require initiation of antiarrhythmic drugs for rhythm control. Inaccurate baseline QTc may cause drug-induced torsades de pointes.
Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF)
Dhanunjaya Lakkireddy, MD,a Adnan Ahmed, MD, a Donita Atkins, RN, a Danish Bawa, MD,a Jalaj Garg, MD, b Jenny Bush, RN,a Rishi Charate, MD, a Sudha Bommana, MP HIL,a Naga Venkata K. Pothineni, MD, a Rajesh Kabra, MD,a Douglas Darden, MD,a Scott Koreber, MD, a Rangarao Tummala, MD, a Chandrashekar Vasamreddy, MD, a Peter Park, MD, a Sanghamitra Mohanty, MD,c Rakesh Gopinathannair, MD,a B. Woun Seo, PHD, d Andrea Natale, MD, c Robert Kennedy, MD
doi : 10.1016/j.jacep.2022.11.026
Volume 9, Issue 4, April 2023, Pages 555-564
Inpatient initiation of sotalol is recommended owing to its proarrhythmic effects.
Something Old, Something New: Reinventing Antiarrhythmic Drug Loading With Intravenous Sotalol∗
Salvatore J. Savona, MD, Emile G. Daoud, MD
doi : 10.1016/j.jacep.2022.12.027
Volume 9, Issue 4, April 2023, Pages 565-568
Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes
Riccardo M. Inciardi, MD, a,b Robert P. Giugliano, MD, SM, c Jeong-Gun Park, P HD, c Francesco Nordio, P HD, c Christian T. Ruff, MD, MPH,c Cathy Chen, MD,d Hans-Joachim Lanz, MD,e Elliott M. Antman, MD, c Eugene Braunwald, MD,c Scott D. Solomon, MD a
doi : 10.1016/j.jacep.2022.11.032
Volume 9, Issue 4, April 2023, Pages 569-580
The risks of heart failure (HF) events compared with stroke/systemic embolic events (SEE) or major bleeding (MB) in heart failure with reduced ejection fraction (HFrEF) vs heart failure with preserved ejection fraction (HFpEF) in a large atrial fibrillation (AF) population have not been well-studied.
Atrial Fibrillation and Heart Failure∗: Too Much Talk and Not Enough Action
Jonathan P. Piccini, MD, MHS
doi : 10.1016/j.jacep.2023.03.003
Volume 9, Issue 4, April 2023, Pages 581-582
Posterior Wall Electrical Isolation in Patients Undergoing Catheter Ablation for Paroxysmal and Nonparoxysmal Atrial Fibrillation
Jorge Romero, MD Dalvert Polanco, MD Mohamed Gabr, MD Isabella Alviz, MD Juan Carlos Diaz, MD David Briceno, MD Alejandro Velasco, MD Kavisha Patel, MD Andrea Natale, MD *Luigi Di Biase, MD, PhD
doi : 10.1016/j.jacep.2022.11.007
Volume 9, Issue 4, April 2023, Pages 583-585
Tafamidis and Incidence of Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
Zachary P. Girvin, MD Austin O. Sweat, MD Stephanie M. Kochav, MD, MPH Mathew S. Maurer, MD Jose Dizon, MD Elaine Y. Wan, MD Angelo Biviano, MD Hasan Garan, MD *Hirad Yarmohammadi, MD, MPH
doi : 10.1016/j.jacep.2022.11.005
Volume 9, Issue 4, April 2023, Pages 586-587
Utility of High-Density 3D-Bipolar Voltage Map After Pulmonary Vein Isolation by Pulsed-Field Ablation
Martin H. Ruwald, MD, PhD Arne Johannessen, MD, DmSc Morten Lock Hansen, MD, PhD Martin Haugdal, MSc Rene Worck, MD, PhD Jim Hansen, MD, DmSc
doi : 10.1016/j.jacep.2022.11.030
Volume 9, Issue 4, April 2023, Pages 588-590
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications
Adam S. Potter, MD, P HD, a,b, * Mohit M. Hulsurkar, P HD, d,e, * Lingling Wu, MD, f Bharat Narasimhan, MD, g Kaveh Karimzad, MD,c Efstratios Koutroumpakis, MD, c Nicolas Palaskas, MD, c Anita Deswal, MD, MPH,c Bharat K. Kantharia, MD, h Xander H.T. Wehrens, MD, PHD d,e,i
doi : 10.1016/j.jacep.2022.11.034
Volume 9, Issue 4, April 2023, Pages 591-602
Recent advances have significantly expanded the options of available therapeutics for cancer treatment, including novel targeted cancer therapies. Within this broad category of targeted therapies is the class of kinase inhibitors (KIs), which target kinases that have undergone aberrant activation in cancerous cells.
Isolation of the Right Superior Pulmonary Vein Requiring Superior Limbus Ablation From the Right Atrium
Martin van Zyl, MD,a Abhishek J. Deshmukh, MBBS, b Samuel J. Asirvatham, MD,b Christopher V. DeSimone, MD, PHD
doi : 10.1016/j.jacep.2023.01.020
Volume 9, Issue 4, April 2023, Pages 603-606
JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
Valentin Fuster, MD, PH D, Editor-in-Chief, Journal of the American College of Cardiology Biykem Bozkurt, MD, P HD, Editor-in-Chief, JACC: Heart Failure Y. Chandrashekhar, MD, DM, Editor-in-Chief, JACC: Cardiovascular Imaging Julia Grapsa, MD, PHD, Editor-in-Chief, JACC: Case Reports Bonnie Ky, MD, Editor-in-Chief, JACC: CardioOncology Douglas L. Mann, MD, Editor-in-Chief, JACC: Basic to Translational Science David J. Moliterno, MD, Editor-in-Chief, JACC: Cardiovascular Interventions Kalyanam Shivkumar, MD, PH D, Editor-in-Chief, JACC: Clinical Electrophysiology Candice K. Silversides, MD, Editor-in-Chief, JACC: Advances Justine Varieur Turco, MA, Divisional Vice President, American College of Cardiology Jian’an Wang, MD, PHD,
doi : 10.1016/j.jacep.2023.03.002
Volume 9, Issue 4, April 2023, Pages 607-609
